2023 Review: Chinese-Sponsored Phase III US Trials See Uptick

But Still Below '21 Level

 
• By Dexter Jie Yan
  
Generate a summary of this article
Listen to this article
Beta

Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.

Clinical study
Chinese drug makers stem fall in number of new US Phase III trials • Source: Shutterstock

Wrapping up a challenging 2023, Chinese pharma firms increasingly ventured into the US to initiate Phase III clinical trials to support future regulatory approvals from the US Food and Drug Administration for their new drug candidates.

Key Takeaways

  • In 2023, as the sole trial sponsor, Chinese firms initiated eight Phase III trial programs that included US sites, reversing a fall in the number to six in 2022 from 11 in 2021.

Last year, as the sole trial sponsor, companies from China commenced a total of eight Phase III programs that included...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By Ellon Xu, Philip Leung, and Grace Shieh

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia